Hinova Pharmaceuticals, Inc. Class ASSE: 688302

"HINOVA PHARMACEUTICALS INC."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

Sep 9, 2026 · Issued by Hinova Pharmaceuticals, Inc. Class A via Shanghai Stock Exchange

Filed with SSE · Sep 9, 2026

Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Hinova Pharmaceuticals, Inc. Class A

"HINOVA PHARMACEUTICALS INC."Announcement on Public Solicitation of Voting Rights by CHINA SECURITIES INVESTOR SERVICES CENTER CO., LTD.Aug 28
"HINOVA PHARMACEUTICALS INC."Announcement on Resolutions of the 18th Meeting of the 2nd Board of DirectorsAug 27
"HINOVA PHARMACEUTICALS INC."Voluntary Disclosure Announcement on Receipt of Notice of Approval for Initiation of a Phase III Clinical Trial of Deuterated Enzalutamide Soft Capsules for High-risk Biochemical Recurrence (BCR) Prostate CancerJul 16
Announcement on Reply to Inquiry Letter for Information Disclosure Supervision of 2025 Annual ReportJun 27

All Hinova Pharmaceuticals, Inc. Class A news releases